ERIE
Erie Indemnity Company
Financial · NASDAQ · Market cap $11.1bn
$243.71
as of 16 Oct 2026, 26% below its 52-week high
Screens as reasonably placed to keep growing its dividend, with low cut-risk signals.
These scores are a resilience check on the dividend, not a recommendation to buy or sell. They are not financial advice.
- Trailing yield
- 2.40%Last 12 months of regular payments at today's price
- Forward yield
- 2.57%Each payment expected in the next 12 months, not the latest one doubled
- Cash cover
- 2.1×Free cash flow over dividends paid
- Earnings cover
- 2.2×Insurers and banks set dividends from capital generation, so their accounting earnings can sit well below the payout.
- 5y dividend growth
- +7.2% a yearLast cut in FY2013
- Next ex-dividend date
- Estimated6 Jan 2027Quarterly dividend of about $1.57
Compared with US companies in Insurance - Property & Casualty (20)
- Trailing yield is higher than 11 of the 17 other US companies in Insurance - Property & Casualty with a yield figure.
- 5y dividend growth (as paid) is lower than 9 of the 17 other US companies in Insurance - Property & Casualty with a 5y growth figure.
Quality
72
ModerateCapacity to keep growing the dividend
Risk
0
LowSignals of dividend-cut pressure
Trim
33
LowHow extended the valuation looks
Why Quality is 72
ERIE against US companies in Insurance - Property & Casualty (20)
Valuation against its own history
As of the last reported period (30 Jun 2026). P80 means the figure is higher than 80% of ERIE’s past readings.
- P/E15.5×P0, good for this measure
- Yield2.4%P57, neutral for this measure
- FCF payout47.6%P8, good for this measure
- DGR 5y-1.2%P29, poor for this measure
- ROIC6.1%P1, poor for this measure
Net debt / EBITDA is left out: for banks and insurers, debt is part of the business, so the ratio says little.
Open valuation historyForecast your income with the ERIE dividend calculator
Inspect surfaces history; it does not predict the future. Nothing here is financial advice or an instruction to buy or sell. Always do your own research. See the Terms of Service.